Artist impression of a breast cancer cell

Breast cancer drug combination to be made available for routine NHS use

Thousands of breast cancer patients will potentially now have access to another potentially life-saving drug combination after amends to draft NICE guidance on a two-drug combination was taken out of the Cancer Drugs Fund (CDF) and entered routine recommendation for use on the NHS.

The draft guidance recommends ribociclib plus fulvestrant as an option for treating a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

The combination is recommended for adults who have had previous endocrine therapy and where another drug option, exemestane plus everolimus, is the most appropriate alternative treatment.

Taken once per day in a pill form, this newly-approved treatment works by inhibiting proteins in cancer cells, thereby preventing the cells from dividing and growing.

Ribociclib has been available through the CDF since 2019, while more evidence was collected to address uncertainties around how much it extends overall survival and its cost-effectiveness.

The new evidence showed that, compared to fulvestrant alone, people taking the combination drug treatment had longer before their disease worsened and also lived longer.

The treatment could be an option for up to 3,300 women.

Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said: “Treatments that can postpone disease progression are important because they can mean some people can avoid the often unpleasant side-effects of chemotherapy, and delay the need for its use in others.

“We are pleased therefore that our original decision to make ribociclib available through the CDF not only gave people access to it earlier than would otherwise have been possible, but has now, through the data collected during that time, allowed us to recommend it for routine use on the NHS.”

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all